Sees FY26 Adjusted EBITDA at $605M-$615M
Sees FY26 adjusted EBITDA $605M-$615M. Sees FY26 CapEx $160M-$170M.
Trade with 70% Backtested Accuracy
Analyst Views on CTEV
About CTEV
About the author
Claritev Scheduled to Announce Q4 Earnings on February 23rd
- Earnings Announcement Schedule: Claritev is set to release its Q4 earnings report on February 23rd after market close, with consensus estimates predicting an EPS of $0.85 and revenue of $241.24 million, indicating investor anticipation for the company's performance.
- Market Expectation Analysis: The consensus EPS and revenue estimates suggest stable profitability for Claritev, and if actual results exceed expectations, it could positively impact the stock price and bolster investor confidence.
- Industry Conference Participation: Claritev presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and showcasing its role as a middleman in a vertically integrated market, potentially attracting more investor interest.
- Historical Performance Review: Claritev's historical earnings data provides crucial insights for assessing future performance, allowing investors to compare past results with current expectations to evaluate the company's growth potential and market competitiveness.
Claritev Reports Q4 Earnings with Mixed Results
- Earnings Report: Claritev's Q4 GAAP EPS of -$4.88 missed expectations by $1.03, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Growth: Despite the EPS miss, Claritev reported revenue of $246.6 million, beating market expectations by $5.36 million, suggesting that the company still possesses growth potential in sales.
- Market Positioning: As a middleman in a vertically integrated market, Claritev faces profitability pressures, yet its positioning may offer strategic opportunities for future development, particularly in the healthcare sector.
- Investor Attention: Claritev presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest that could pave the way for future financing and partnership opportunities.
Claritev to Present at 2026 J.P. Morgan Healthcare Conference, Enhancing Healthcare Affordability
- Conference Participation: Claritev Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its innovations in healthcare technology, which is expected to attract investor attention and enhance the company's visibility.
- Technological Edge: As a company focused on healthcare affordability and transparency, Claritev leverages over 40 years of claims repricing experience and AI technology to provide data-driven solutions aimed at optimizing healthcare networks and benefits design.
- Market Coverage: Claritev serves over 700 healthcare payors, more than 100,000 employers, 60 million consumers, and 1.4 million contracted providers, demonstrating its extensive influence and market penetration within the healthcare industry.
- Strategic Goals: By offering purpose-built solutions, Claritev aims to support all key stakeholders, including payors, employers, and patients, thereby promoting accessibility and fairness in healthcare services, aligning with current trends in healthcare reform.
Claritev Shares Drop 20% Following Sale of 1.5 Million Shares by Stockholders
Stock Price Decline: Claritev Corporation (CTEV) experienced a significant drop of 20.5%, closing at $46.6, following the announcement of a public offering of 1,500,000 shares of Class A common stock by existing stockholders.
Underwriter Options: The underwriters were granted a 30-day option to purchase an additional 225,000 shares, but Claritev will not receive any proceeds from this offering as all shares are sold by current holders.
Market Reaction: The market reacted negatively to the increased float and selling pressure, with CTEV's trading volume surging above normal levels as investors processed the offering details.
Stock Performance: On the day of the announcement, CTEV opened at $57.98, reached a high of $58.10, and a low of $46.25, with a previous close of $58.62, and its 52-week trading range is noted to be $41.70 - $68.90.
Claritev Corporation Reports Reduced Losses in Q3
Third Quarter Loss: Claritev Corporation reported a loss of -$69.753 million for the third quarter, an improvement from last year's loss of -$391.450 million.
Earnings Per Share: The company's earnings per share (EPS) were -$4.23, compared to -$24.25 in the same quarter last year.
Revenue Growth: Revenue increased by 6.7% to $245.959 million, up from $230.495 million a year ago.
Revised Outlook: Claritev has updated its full-year revenue growth forecast to 2.8% to 3.2% and adjusted its capital expenditure guidance to $165 million to $175 million.
Claritev Invests in Klaim to Improve Provider Payment Services in the US and MENA Regions
Investment Announcement: Claritev (CTEV) announced its investment in Klaim to facilitate the launch of a co-branded payment solution.
Strategic Partnership: The investment aims to enhance collaboration between Claritev and Klaim in the payment processing sector.
Claritev Scheduled to Announce Q4 Earnings on February 23rd
- Earnings Announcement Schedule: Claritev is set to release its Q4 earnings report on February 23rd after market close, with consensus estimates predicting an EPS of $0.85 and revenue of $241.24 million, indicating investor anticipation for the company's performance.
- Market Expectation Analysis: The consensus EPS and revenue estimates suggest stable profitability for Claritev, and if actual results exceed expectations, it could positively impact the stock price and bolster investor confidence.
- Industry Conference Participation: Claritev presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the healthcare sector and showcasing its role as a middleman in a vertically integrated market, potentially attracting more investor interest.
- Historical Performance Review: Claritev's historical earnings data provides crucial insights for assessing future performance, allowing investors to compare past results with current expectations to evaluate the company's growth potential and market competitiveness.
Claritev Reports Q4 Earnings with Mixed Results
- Earnings Report: Claritev's Q4 GAAP EPS of -$4.88 missed expectations by $1.03, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Growth: Despite the EPS miss, Claritev reported revenue of $246.6 million, beating market expectations by $5.36 million, suggesting that the company still possesses growth potential in sales.
- Market Positioning: As a middleman in a vertically integrated market, Claritev faces profitability pressures, yet its positioning may offer strategic opportunities for future development, particularly in the healthcare sector.
- Investor Attention: Claritev presented at the 44th Annual J.P. Morgan Healthcare Conference, garnering investor interest that could pave the way for future financing and partnership opportunities.
Claritev to Present at 2026 J.P. Morgan Healthcare Conference, Enhancing Healthcare Affordability
- Conference Participation: Claritev Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its innovations in healthcare technology, which is expected to attract investor attention and enhance the company's visibility.
- Technological Edge: As a company focused on healthcare affordability and transparency, Claritev leverages over 40 years of claims repricing experience and AI technology to provide data-driven solutions aimed at optimizing healthcare networks and benefits design.
- Market Coverage: Claritev serves over 700 healthcare payors, more than 100,000 employers, 60 million consumers, and 1.4 million contracted providers, demonstrating its extensive influence and market penetration within the healthcare industry.
- Strategic Goals: By offering purpose-built solutions, Claritev aims to support all key stakeholders, including payors, employers, and patients, thereby promoting accessibility and fairness in healthcare services, aligning with current trends in healthcare reform.
Claritev Shares Drop 20% Following Sale of 1.5 Million Shares by Stockholders
Stock Price Decline: Claritev Corporation (CTEV) experienced a significant drop of 20.5%, closing at $46.6, following the announcement of a public offering of 1,500,000 shares of Class A common stock by existing stockholders.
Underwriter Options: The underwriters were granted a 30-day option to purchase an additional 225,000 shares, but Claritev will not receive any proceeds from this offering as all shares are sold by current holders.
Market Reaction: The market reacted negatively to the increased float and selling pressure, with CTEV's trading volume surging above normal levels as investors processed the offering details.
Stock Performance: On the day of the announcement, CTEV opened at $57.98, reached a high of $58.10, and a low of $46.25, with a previous close of $58.62, and its 52-week trading range is noted to be $41.70 - $68.90.
Claritev Corporation Reports Reduced Losses in Q3
Third Quarter Loss: Claritev Corporation reported a loss of -$69.753 million for the third quarter, an improvement from last year's loss of -$391.450 million.
Earnings Per Share: The company's earnings per share (EPS) were -$4.23, compared to -$24.25 in the same quarter last year.
Revenue Growth: Revenue increased by 6.7% to $245.959 million, up from $230.495 million a year ago.
Revised Outlook: Claritev has updated its full-year revenue growth forecast to 2.8% to 3.2% and adjusted its capital expenditure guidance to $165 million to $175 million.
Claritev Invests in Klaim to Improve Provider Payment Services in the US and MENA Regions
Investment Announcement: Claritev (CTEV) announced its investment in Klaim to facilitate the launch of a co-branded payment solution.
Strategic Partnership: The investment aims to enhance collaboration between Claritev and Klaim in the payment processing sector.
